Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chen, Y.-M.
Right arrow Articles by Tsai, C.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.-M.
Right arrow Articles by Tsai, C.-M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 25:32-36 (1995)
© 1995 Foundation for Promotion of Cancer Research

Superior Vena Cava Syndrome Revisited

Yuh-Min Chen1,2,, Shuling Yang2, Reury-Perng Perng1 and Chun-Ming Tsai1

1 Chest Department, Veterans General Hospital-Taipei Taipei
2 Cancer Clinical Research Center, Institute of Biomedical Sciences Academia Sinica, Taipei

For reprints and all correspondence: Yuh-Min Chen, Chest Department, Veterans General Hospital-Taipei, Shih-pai, Taipei, Taiwan, ROC

Received November 11, 1994; accepted January 23, 1995

A clinical review with analysis of prognostic factors, including the impact of the initial management modality, was conducted on 137 patients with superior vena cava syndrome (SVCS) seen at the Veterans General Hospital-Taipei between 1989 and 1993. Malignant diseases account for most of the SVCS in our Chinese patients. Patients received diagnostic intervention for their underlying diseases without obvious complications. Whether or not there is a development of SVCS in lung cancer patients, showed prognostic significance in non-small cell lung cancer (NSCLQ 'and no significance in small cell lung cancer (SCLQ. Those with SVCS as the initial manifestation of malignant disease had a poor prognosis compared to those who developed SVCS later. Survival is best in lymphoma/leukemia patients, followed by malignant thymoma and SCLC, and worst in NSCLC and metastatic cancer. The rapid onset of symptoms from SVCS had a short median survival in lung cancer and significantly compromised survival in SCLC. The overall survival of SCLC with SVCS was not affected, regardless of whether the initial therapy had been radiotherapy or chemotherapy

Key Words: Superior vena cava syndrome • Small cell lung cancer • Non-small cell lung cancer • Chemotherapy • Radiotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.